Study on Oral Q702 and Pembrolizumab for Advanced Esophageal, Gastric, Liver, and Cervical Cancers

Sponsor: Qurient Co., Ltd.

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT05438420

Provider View

This clinical trial is testing the safety and initial effectiveness of a new drug, Q702, when used with pembrolizumab in patients with advanced esophageal, gastric, liver, and cervical cancers that have not responded to previous treatments.

Patient Parameters

Program Overview

The purpose of this study is to evaluate the safety and early effectiveness of a new oral medication, Q702, in combination with pembrolizumab for patients with advanced esophageal, gastric, liver, and cervical cancers. These patients have previously been treated with anti-PD1 or anti-PD-L1 therapies but their cancer has continued to progress.

Eligibility Criteria

Inclusion Criteria

  • Must provide written consent to participate in the trial.
  • Have a confirmed diagnosis of advanced or metastatic esophageal, gastric, liver, or cervical cancer.
  • Cancer must have progressed after treatment with anti-PD1 or anti-PD-L1 therapies, either alone or with other treatments.
  • Must have measurable cancer as determined by standard medical criteria.
  • Must be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
  • Must have a life expectancy of at least 3 months.

Exclusion Criteria

  • Women who are pregnant or breastfeeding.
  • Use of certain medications that affect liver enzymes within a specific time before starting the study and during the trial.
  • Have received radiation therapy within 2 weeks before starting the study or have a history of lung inflammation due to radiation.
  • Have had a tissue or organ transplant from another person.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.